Breaking Ground in Biotech: The Role of AI and Gene Editing, Part 1

AI and Generative Biology: Authoring Life, Redesigning Healthcare, and Building Guardrails: Physician and molecular biologist Dr. Adrian Woolfson, co-founder of Genyro (https://www.genyro.com/) , a biotechnology company specializing in synthetic genome design and construction, and author of “On the Future of Species: Authoring Life by Means of Artificial Biological Intelligence (https://amzn.to/3QTi9Dd) ,” discusses the convergence of AI with synthetic/generative biology that could make biology programmable and enable genome design and construction beyond traditional gene editing. Woolfson argues that the technology is morally neutral but is arriving rapidly and requires public awareness, governance, and guardrails due to risks, including misuse by authoritarian regimes and biological warfare. He discusses evolution’s trade-offs and why he favors limiting human applications to curing disease and extending healthy longevity, while opposing germline modification; he explains germline vs somatic editing and cites the flawed, unethical case of a Chinese scientist attempting inherited HIV resistance. They examine sickle cell disease cures costing $2–$3 million, scalability issues, and trade-offs like malaria protection, and highlight non-medical benefits such as engineered crops, biomaterials, desalination, and DNA-based information storage.